Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia

Rheumatology International
Juan Carlos Cataño, Milena Morales

Abstract

The use of biological therapy has been linked with an increased risk of tuberculosis (TB) reactivation. The aim of this study was to present the follow-up results for isoniazid (INH) chemoprophylaxis in patients receiving different biological therapies. In this prospective observational study, patients with latent tuberculosis infection (LTBI) were given INH chemoprophylaxis between 2 and 9 months prior to the beginning of biological therapy. All patients were followed up monthly for any signs or symptoms of active TB or INH toxicity. A total of 221 patients, 122 females (55.2 %), with a mean age of 46.8 ± 11.3 years (16-74) were enrolled. LTBI was identified in 218 patients (98.7 %), all of whom received INH chemoprophylaxis. Seven patients (3.2 %) developed active tuberculosis, and 32 (17.2 %) patients developed intolerance or toxicity related to INH. Chemoprophylaxis with INH seems to be effective and safe for the prevention of most TB reactivation in individuals with LTBI, but toxicity must be monitored during follow-up.

References

Mar 5, 2003·The Lancet Infectious Diseases·Michael A GardamDonald C Vinh
Aug 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul BrassardSamy Suissa
Dec 18, 2009·Journal of Leukocyte Biology·Paolo SfrisoAndrea Doria
Jul 27, 2010·Rheumatology International·Muhammad HaroonJoe Devlin
Nov 8, 2011·JAMA : the Journal of the American Medical Association·Carlos G GrijalvaJeffrey R Curtis
Apr 24, 2012·Annals of the Rheumatic Diseases·K L WinthropL J Herrinton
Jun 4, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Xi XieJia Wang

❮ Previous
Next ❯

Citations

Mar 12, 2016·International Journal of Mycobacteriology·Lingaraja Jena, Bhaskar C Harinath
Mar 25, 2018·Pharmacoepidemiology and Drug Safety·Christopher PeaseGonzalo G Alvarez
Sep 1, 2018·International Journal of Rheumatic Diseases·Vineeta ShobhaK R Anupama
May 5, 2016·Zeitschrift für Rheumatologie·A Zink, K Albrecht
Jan 14, 2017·Microbiology Spectrum·Juan Carlos Cataño, Jaime Robledo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.